Successful results of a University of Liverpool-led trial that utilised nanotechnology to improve drug therapies for HIV patients has been presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, a leading annual conference of HIV research, clinical practice and progress.
The healthy volunteer trial, conducted by the collaborative nanomedicine research programme led by Pharmacologist Professor Andrew Owen and Materials Chemist Professor Steve Rannard, and in collaboration with the St Stephen’s AIDS Trust at the Chelsea & Westminster Hospital in London, examined the use of nanotechnology to improve the delivery of drugs to HIV patients. The results were from two trials which are the first to use orally dosed nanomedicine to enable HIV therapy optimisation.
Manipulation of matter
Nanotechnology is the manipulation of matter on an atomic, molecular, and supramolecular scale. Nanomedicine is the application of nanotechnology to the prevention and treatment of disease in the human body. By developing smaller pills that are better for patients and less expensive to manufacture, this evolving discipline has the potential to dramatically change medical science and is already having an impact in a number of clinically used therapies and diagnostics worldwide.
Currently, the treatment of HIV requires daily oral dosing of HIV drugs, and chronic oral dosing has significant complications that arise from the high pill burden experienced by many patients across populations with varying conditions leading to non-adherence to therapies.
Developing new therapies
Recent evaluation of HIV patient groups have shown a willingness to switch to nanomedicine alternatives if benefits can be shown. Research efforts by the Liverpool team have focused on the development of new oral therapies, using Solid Drug Nanoparticle (SDN) technology which can improve drug absorption into the body, reducing both the dose and the cost per dose and enabling existing healthcare budgets to treat more patients.
The trial results confirmed the potential for a 50 percent dose reduction while maintaining therapeutic exposure, using a novel approach to formulation of two drugs: efavirenz (EFV) and, lopinavir (LPV). EFV is the current WHO-recommended preferred regimen, with 70% of adult patients on first-line taking an EFV-based HIV treatment regimen in low- and middle-income countries.
The trial is connected to the University’s ongoing work as part of the multinational consortium OPTIMIZE, a global partnership working to accelerate access to simpler, safer and more affordable HIV treatment. Funded by the U.S. Agency for International Development, OPTIMIZE is led by the Wits Reproductive Health & HIV Institute in Johannesburg, South Africa, and includes the interdisciplinary Liverpool team, Columbia University, Mylan Laboratories and the Medicines Patent Pool (MPP). OPTIMIZE is supported by key partners including UNITAID and the South African Medical Research Council (SAMRC).
Benny Kottiri, USAID’s Office of HIV/AIDS Research Division Chief, said: “The potential applications for HIV treatment are incredibly promising. By aligning efforts, these integrated investments offer the potential to reduce the doses required to control the HIV virus even further, resulting in real benefits globally. This would enable the costs of therapy to be reduced which is particularly beneficial for resource-limited countries where the burden of disease is highest.”
To watch the presentation please click here.
Receive an email update when we add a new HIV article.
The Latest on: HIV
via Google News
The Latest on: HIV
- HIV prevention drug PrEP to be evaluated for State funding on October 7, 2018 at 4:42 pm
Health authorities have begun a formal process to evaluate the possibility of introducing a State-funded HIV prevention drug. The anti-HIV Pre-Exposure Prophylaxis (PrEP) is already available for purc... […]
- In a first, HIV-positive mother donates liver to save her child's life on October 7, 2018 at 2:37 am
JOHANNESBURG, South Africa (AFP) — Faced with the only chance to save a child's life, doctors in South Africa have performed a medical first — transplanting part of the liver from an HIV ... […]
- Doravirine Works Well as First-Line or Switch Option for HIV on October 5, 2018 at 10:57 am
SAN FRANCISCO -- A once-daily combination pill containing doravirine offers good HIV suppression when used as first-line treatment or as a switch option for people with undetectable viral load, resear... […]
- Good signs after HIV-positive mother donates liver tissue to daughter on October 5, 2018 at 10:43 am
Editor’s note: The opinions in this article are the author’s, as published by our content partner, and do not represent the views of MSN or Microsoft. One year on from a world-first liver transplant b... […]
- New details of HIV life cycle on October 5, 2018 at 9:27 am
The discovery of a small molecule that plays an important part of the HIV life cycle may lead to the development of new treatments for the virus. Research by a multi-institutional team, including two ... […]
- Doctors Transplant Liver of HIV-Positive Mother to Save Her Dying Child on October 5, 2018 at 8:41 am
Doctors in South Africa transplanted part of the liver of an HIV-positive mother to her dying child — who did not have HIV — in a last-ditch effort to save the child. The doctors decided that ... […]
- HPV Subtypes Strongly Linked to HIV Infection Uncovered on October 5, 2018 at 8:14 am
A team of scientists led by investigators at the University of California, Riverside (UCR) has identified the individual subtypes of HPV that are strongly linked to HIV infections. While it has been k... […]
- Study links individual HPV types to HIV infection on October 5, 2018 at 8:04 am
RIVERSIDE, Calif. -- An international research team led by a scientist at the University of California, Riverside, has for the first time identified individual types of the human papillomavirus, or HP... […]
- Despite Infectious Disease Outbreaks Linked To Opioid Crisis, Most Substance Abuse Facilities Don’t Test For HIV Or HCV on October 5, 2018 at 6:46 am
America’s opioid epidemic continues to take lives at a staggering rate. According to preliminary estimates from the Centers for Disease Control and Prevention (CDC), drug overdoses killed about 72,000 ... […]
via Bing News